Source - SMW
Shire confirmed that it has received Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A.




At 1:19pm: (LON:SHP) Shire PLC share price was -2.5p at 3656.5p



Related Charts

Shire (SHP)

0.00 (0.00%)
delayed 17:30PM